AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05347147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Presendin
Description: Presendin is supplied as 2 parts, one vial consisting of a drug part (white or greyish white powder in a clear vial) and one pre-filled syringe containing the diluent part (colourless liquid). The drug part is suspended in the diluent part solution and administered SC as a suspension.
Study NCT05347147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as 2 parts (visually identical to the Presendin vial and pre-filled diluent syringe). The drug part will exclude the active pharmaceutical ingredient (exenatide acetate) and the diluent part will be the same as the active treatment diluent. The drug part is suspended in the diluent part solution and administered SC as a suspension.
Study NCT06273683 — intervention group
Intervention type: OTHER
Intervention: Hand-held bipolar energy instrument
Description: A bipolar energy instrument is used for complete salpingectomy at the time of cesarean delivery.
Study NCT06273683 — intervention group
Intervention type: OTHER
Intervention: Traditional suture ligation
Description: Traditional suture ligation technique is used for complete salpingectomy at the time of cesarean delivery.
Study NCT06089369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab (9 cycles)
Description: IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 9 cycles）
Study NCT06089369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab (18 cycles)
Description: IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles）
Study NCT06089369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active surveillance
Description: Active surveillance
Study NCT04729400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Myofascial Therapy device
Description: Therapeutic Percutaneous Electrolysis and Vacuum Myofascial Therapy device once week for four weeks associated with eccentric exercises devices at home.
Study NCT04729400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy program
Description: The multimodal physical therapy program includes 10 sessions of ultrasound pulsatil therapy (US) and massage associated with eccentric exercises devices at home.
Study NCT04729400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Percutaneous Electrolysis
Description: Therapeutic Percutaneous Electrolysis
Study NCT04729400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound pulsatil therapy (US) and massage
Description: ultrasound pulsatil therapy (US) and massage
Study NCT05675683 — intervention group
Intervention type: DRUG
Intervention: Capmatinib
Description: Patients receiving Capmatinib
Study NCT05280847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: fascial plane injection using ultrasound and fluoroscopic guidance
Study NCT05377073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hatha Yoga
Description: Patients in the yoga group performed warm-up exercises for 10 minutes, standing, sitting and supine positions of Hatha yoga (30 minutes), and relaxation and breathing exercises (20 minutes). The program consisted of one weekly session for a total of eight weeks.
Study NCT05377073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Patients in the stretching group performed warm-up activities (10 minutes), and analytic stretching exercises targeting the following muscles: sternocleidomastoid, splenius, trapeze, triceps, posterior shoulder capsule, paravertebralis, hamstrings, quadriceps, gastrocnemius, soleus and tibialis anterior (40 minutes). Two repetitions of 15 seconds of each stretch were performed, with a 15 seconds interval between repetitions. The sessions ended with diaphragmatic breathing exercises (10 minutes). The program consisted of one weekly session for a total of eight weeks.
Study NCT05368454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Diabetes Self-Management Education and Support (DSMES) Program
Description: An online program for Diabetes Self-Management, Education and Support (DSMES) that includes personal coaching by a certified Diabetes Care and Education Specialist (CDCES), tracking tools, and FreeStyle Libre CGMs, a wearable sensor with data scanning ability accessed through the smartphone app.
Study NCT05368454 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: All participants randomized to the standard of care/control arm will be asked to continue with their current care plan and care team for management of their diabetes.
Study NCT05392933 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound guided piriformis muscle lidocaine injection
Description: Ultrasound guided piriformis muscle (piriformis syndrome) 5 ml %2 lidocaine injection
Study NCT05891964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab Injection
Description: Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.
Study NCT05150444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive and physical exercise training
Description: 12 weeks (3 times a week): patients will cycle on an adapted ergometer during their dialysis procedure. The exercise program will be run by kinesiologists. Participants will start with 15 minutes of cycling and then gradually increase the time and intensity. After the physical exercise session, they will continue with cognitive training. This training will be done on a tablet computer on a CogniFit platform (\~30 minutes). The brain games on mentioned platform automatically adapt to individual cognitive abilities.
Study NCT04690205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: End of Life (EOL) Care at at Home
Description: Remote monitoring and home-based care designed for patients with advanced hematologic malignancies
Study NCT06198140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release and quick icing
Description: In experimental group the individuals will receive myofascial release and quick icing. Quick icing will be on ankle dorsiflexors by using ice pack in the target area. Quick icing will be applied for 10 minutes (time of application 10 seconds and a rest for 20 seconds). This treatment protocol will be 6 times/week for 4 weeks in the hospital setting. Mayofascial release will be given on the target ankle planterflexors. The subjects who will receive Myofascial Release will be positioned in prone with the treatment area exposed. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied with different levels by following longitudinal movements according to subject's tolerance for duration of 3 minutes in each sitting. Patients will be given a rest time after each level in order to allow the tissue to soften. This treatment protocol will be 6 times/week for 4 weeks in the hospital setting.
Study NCT06198140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myofascial release
Description: In control group the individuals will receive only myofascial release on ankle planterflexors. The subjects who will receive Myofascial Release will be positioned in prone with the treatment area exposed. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied with different levels by following longitudinal movements according to subject's tolerance for duration of 3 minutes in each sitting. Patients will be given a rest time after each level in order to allow the tissue to soften. This treatment protocol will be 6 times/week for 4 weeks in the hospital setting.
Study NCT05037188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose BCD-250 injection
Description: A recombinant viral vector AAV5-RBD-S vaccine
Study NCT05037188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose BCD-250 injection
Description: A recombinant viral vector AAV5-RBD-S vaccine
Study NCT05037188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose or high dose BCD-250 injection
Description: A recombinant viral vector AAV5-RBD-S vaccine
Study NCT05037188 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo injection
Study NCT06341803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individually Neuronavigated accelerated intermittent theta burst stimulation with Magpro X100
Description: MagproX 100 and Axilium Cobot with Localite camera
Study NCT05699902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECs block during mastectomy
Description: The patients were randomised to receive a PECS block consisting of 30 ml of levobupivacaine 0.25% after induction of anaesthesia (PECS group) or a saline mock block (control group). The patients answered a 40-item QoR questionnaire (QoR-40) before and 1 day after breast cancer surgery. MAIN OUTCOME MEASURES
Study NCT05699902 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham block
Description: Female undergone mastectomy and have received conventional analgesic methods
Study NCT06310629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula
Description: High Flow Nasal Cannula
Study NCT04676009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise arm :
Description: Patients will receive physical activity recommendations at inclusion.~At each treatment cure, patients will receive pre-exercise nutritional recommendations and an acute physical exercise prior to immunotherapy and chemotherapy. The acute physical exercise will last 35 minutes and will be intermittent and individualized based on the results obtained by the patient during an endurance test on a ergocyle performed prior to treatment.~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place before exercise (1), after exercise (2) and 12 hours after the start of treatment (3).~A nutritional assessment will be carried out during the first and last treatment cure.~They will also benefit a home walking program. These patients will have to wear an activity tracker tracker during all intervention (3 months).~They will have a phone follow-up every 10 days (± 3 days) after each treatment cure for the study duration.
Study NCT05112341 — intervention group
Intervention type: RADIATION
Intervention: radiation therapy
Description: the patient first is simulated then delineation is done
Study NCT06310629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrinseque Health Non-Rebreathing Mask (IHNRM)
Description: Intrinseque Health Non-Rebreathing Mask (IHNRM)
Study NCT05139147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAISe Thrombectomy System
Description: DAISe Thrombectomy System for mechanical thrombectomy
Study NCT06461884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percussions
Description: Group A: Percussions and diaphragmatic breathing exercise will be performed with 1 session a day for total 3 days in a week for 4 weeks
Study NCT04609748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oil
Description: Cannabidiol oil will be given twice a day, in a dose of 33,6mg, applied orally. The therapy will last 15 days.
Study NCT04609748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimesulide
Description: Nimessulid will be given twice a day - 2x100mg, applied orally. The therapy will last 15 days.
Study NCT04871815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium pyruvate nasal spray
Description: Subjects will use a sodium pyruvate nasal spray 3x daily for 7 days.
Study NCT05720312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Patterned pulsed magnetic stimulation delivered using an electromagnet. We will use a MagVenture rTMS device and a Cool-B65 coil.
Study NCT06461884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: , Diaphragmatic breathing exercise
Description: Group B: Diaphragmatic breathing exercise will be performed with 1 session a day for total 3 days in a week for 4 weeks
Study NCT06380660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-86225106 tablet
Description: ACE-86225106 will be administered orally daily as a continuous regimen. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
Study NCT04866914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for Insomnia
Description: ACT-I treatment group: Participants diagnosed with chronic insomnia will receive group treatment. The six sessions will be aimed at psychoeducation about sleep added to the therapeutic processes of acceptance, mindfulness, availability, values, defusion and commitment, used in ACT.
Study NCT04866914 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Active control group CBT-I: Participants diagnosed with chronic insomnia will receive treatment in a group. The six sessions will be aimed at cognitive-behavioral components, such as education and sleep hygiene, stimulus control, sleep restriction and demystification / restructuring of belief beliefs.
Study NCT05356728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thealoz Duo (combination of trehalose and hyaluronate) eye drop and Hyabak (hyaluronate) eye drop
Description: One of the eyes will be assigned to use Thealoz Duo while the other with Hyabak by using randomisation table
Study NCT04649372 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: EndoVE
Description: On the day of the procedure, a review of any changes which occurred since the pre-study visit will be conducted. The patient will be placed under general anaesthesia or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes.
Study NCT04575792 — intervention group
Intervention type: BEHAVIORAL
Intervention: Practicing oral habits
Description: children who practice one or more of the specified oral habits ( mouth breathing, object sucking, or tongue thrusting) are considered exposed.
Study NCT05353140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The WATCHMAN/WATCHMAN FLX device
Description: Watchman device was an umbrella-shaped, self-expanding, nitinol structure with a porous partial polyethylene terephthalate membrane (160 um mesh) and 10 struts. The membrane portion of the structure faces into the body of the left atrial to block embolization of thrombus and provide scaffolding on which endothelialization can occur. The On July 21st, 2020, the FDA approved the next generation LAAO device, named Watchman FLX. This newiteration of the Watchman LAAO platform offers full capability of recapture and redeployment of the device, decreasedmetallic exposure, an increased number of contact points for sealing, a fully rounded delivery shape, and precision anchors designed to provide optimal device engagement with the LAA.
Study NCT05353140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban + Clopidogre
Description: Previous pivotal trials have shown that in patients with atrial fibrillation and requiring antiplatelet treatment, a NOAC plus clopidogrel regimen was associated with a lower incidence of bleeding events as compared with a warfarin-based triple antithrombotic strategy. Therefore, the current expert opinions and consensus of North American Societies recommend a NOAC plus a P2Y12 inhibitor in patients with AF and PCI. In the present study, Rivaroxaban + Clopidogre are required for 45 days in LAAO group after LAAO.
Study NCT05353140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban + Clopidogre
Description: Previous pivotal trials have shown that in patients with atrial fibrillation and requiring antiplatelet treatment, a NOAC plus clopidogrel regimen was associated with a lower incidence of bleeding events as compared with a warfarin-based triple antithrombotic strategy. Therefore, the current expert opinions and consensus of North American Societies recommend a NOAC plus a P2Y12 inhibitor in patients with AF and PCI. In the present study, Rivaroxaban + Clopidogre are required for 45 days in LAAO group after LAAO.
Study NCT05353140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel
Description: Aspirin + Clopidogrel are required from 46 days to 12 months after LAAO.
Study NCT05612412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morning Exercise
Description: Standardized treadmill exercise session starting at approximately 0700
Study NCT05612412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evening Exercise
Description: Standardized treadmill exercise session starting at approximately 1800
Study NCT05763355 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: Biopsies will be performed under local anaesthesia. In all patients with a suspicious lesion (PIRADSv2.1 3-5) noted on the mp-MRI, the software-based image fusion biopsies will be obtained collecting 3 to 5 cores per target area according to its volume, 10-12 systematic cores of the remaining areas of the prostate will be collected from sectors specified in the PIRADSv2.1 prostate map.
Study NCT06115902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for injection
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
Study NCT05754138 — intervention group
Intervention type: DEVICE
Intervention: Sport SICD
Description: Follow up
Study NCT05515718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pain management
Description: Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician, under strict aseptic conditions After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
Study NCT05515718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Description: Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician under strict aseptic conditions, immediately after oral informed consent is obtained. After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
Study NCT05043311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: intramuscular injection
Study NCT05970887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine
Description: The bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine is a combination of 15-µg of mRNA encoding the wild-type (WT) spike protein and 15-µg of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariant.
Study NCT05970887 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine
Description: The bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine is a combination of 15-µg of mRNA encoding the wild-type (WT) spike protein and 15-µg of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariant.
Study NCT05970887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent influenza vaccine
Description: The quadrivalent influenza vaccine is an inactivated vaccine containing 15μg HA/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2022-2023 northern hemisphere season
Study NCT05970887 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: quadrivalent influenza vaccine
Description: The quadrivalent influenza vaccine is an inactivated vaccine containing 15μg HA/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2022-2023 northern hemisphere season
Study NCT05215522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The BCI-FES Intervention
Description: To evaluate whether the participant can effectively control FES using the developed remote BCI system. Thus, participants will receive a three-week BCI-FES intervention at their home, including three sessions of intervention per week. Each session will last around 60 minutes, including 10 minutes of preparation, 40 minutes of intervention and 10 minutes interview on the user's experience with the device and any experienced side effects, if any.
Study NCT06192121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web Based Education
Description: In this research, a reminder message will be sent 3 times a week along with web-based training.
Study NCT06456710 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Conventional IBS Health Education
Description: Patients were provided with IBS related knowledge (e.g., the pathogenesis of IBS and the reasons affecting the treatment effect), exercise guidance, drug guidance and dietary management precautions; and timely answers to patients' clinical problems and psychological support.
Study NCT06456710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Based on ACT Theory of Psychological Intervention
Description: On the basis of the control group, the stigma intervention program of college students with IBS based on ACT theory was implemented. The duration of intervention was 40 to 50 minutes for 6 times, once a week for 6 weeks.~Week1: established relationships; introduced the core contents of ACT, the treatment process, and the effects of application.~Week2: encouraged to express negative emotions and behaviors; made patients accept the disease.~Week3: explained the importance of coping with negative emotions; instructed to separate negative thoughts from reality through cognitive dissociation exercises.~Week4: changed the concept of self and actively accepted IBS; guided to focus on the current life and true self.~Week5: introduced the values in ACT; helped clarify the values; guided to build confidence and focused on the core values.~Week6: introduced the importance of commitment to action; developed goals and plans together; encouraged to strengthen the use of ACT.